8 Analysts Assess Altimmune: What You Need To Know
Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Cue Biopharma (CUE) and Atricure (ATRC)
Altimmune's Strategic Positioning and Promising Future in Obesity and MASH Treatment Markets
H.C. Wainwright Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Altimmune, Maintains $12 Price Target
Altimmune's Pemvidutide: A Promising Best-in-Class Therapy With Broad Potential and Strong Buy Rating
The tariff war between the US and Europe is escalating, and Trump's 'tariff big stick' is making the pharmaceutical industry tremble.
Pharmaceutical companies are urging the Trump administration and EU officials to exclude Medical products from the escalation of the trade war.
Key Deals This Week: ServiceNow, Eaton, Crown Castle, Victoria's Secret and More
A Quick Look at Today's Ratings for Altimmune(ALT.US), With a Forecast Between $18 to $25
Altimmune Soars Amid Takeover Speculation
Altimmune Call Volume Above Normal and Directionally Bullish
Express News | Watching Altimmune; Traders Ciruclate M&A Blog Comments Suggesting Multiple Large Pharma Co's Interested In The Company
Evercore Bullish on Altimmune, Likes Drug Move Into Alcohol Related Disease
Altimmune Price Target Maintained With a $25.00/Share by Citizens Capital Markets
Altimmune Analyst Ratings
Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders
Express News | Altimmune Shares up 4.5% on Plans to Test Obesity Drug for Alcohol Use Disorder, Other Conditions
Insider Purchase: Chief Financial Officer of $ALT Buys 10,000 Shares
JMP Securities Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Promising Potential of Altimmune's Pemvidutide Drives Buy Rating Amid Expanding Indications and Strong Market Outlook